Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

William Y. Kim, MD, a Damon Runyon Scientist

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
79 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Sep 12, 2011

Bladder cancer is a prevalent and deadly disease, the fourth most common cancer in men. Billy is conducting a clinical trial examining the efficacy of erlotinib/Tarceva, an EGFR (epidermal growth factor receptor) inhibitor drug, in bladder cancer. His goal is to define predictors of patient response to erlotinib and other EGFR inhibitors and determine how to best coordinate EGFR inhibition with chemotherapy. These studies should have direct clinical impact on this deadly disease, allowing the treatment of patients most likely to benefit while minimizing unnecessary toxicity in those unlikely to respond.

Learn more at www.damonrunyon.org

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (2)

Sign In or Sign Up now to post a comment!
  • want to know something that Bill Kim and the Damon Runyon Fund and ASIO (aka the mickey mouse club) and the australian government dont want anyone to know.........go to "eurogliders heaven must be there nzoz1984" and press "see all" to find my 3 hidden comments.

  • hallelujah!

Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more